Paola Maffi1, Antonio Secchi2. 1. Diabetes Research Institute - Internal Medicine and Transplant Unit, IRCCS Scientific Institute Ospedale San Raffaele, Milan, Italy. paola.maffi@hsr.it. 2. Internal Medicine and Transplant Unit, Vita-Salute San Raffaele University, Milan, Italy.
Abstract
PURPOSE OF REVIEW: In patients with type 1 diabetes with extreme glycemic variability, the restoration of pancreas endocrine function is potentially and completely achieved with islets of Langerhans (tissue derived from whole organ) or pancreas (whole organ) transplantation. The aim of our review is to report on the latest studies and to highlight the benefits and risks of the two procedures, providing clearer, more selective, evidence-based clinical indications that also consider the impact on the degenerative complications of diabetes as a potential benefit. RECENT FINDINGS: Clinical experience in this field has been dynamic over the last three decades, and has been characterized by the development of more standardized protocols and a clearer definition of clinical outcome. On the contrary, the recommendations thus far are not well delineated and tend to overlap, and the past ADA position statement for pancreas transplant alone has also been applied to islet transplant alone, without differentiation. Both outcome-driven and non-outcome-driven criteria are considered in the conclusions, in an attempt to streamline indications for islet-alone or pancreas-alone transplantation.
PURPOSE OF REVIEW: In patients with type 1 diabetes with extreme glycemic variability, the restoration of pancreas endocrine function is potentially and completely achieved with islets of Langerhans (tissue derived from whole organ) or pancreas (whole organ) transplantation. The aim of our review is to report on the latest studies and to highlight the benefits and risks of the two procedures, providing clearer, more selective, evidence-based clinical indications that also consider the impact on the degenerative complications of diabetes as a potential benefit. RECENT FINDINGS: Clinical experience in this field has been dynamic over the last three decades, and has been characterized by the development of more standardized protocols and a clearer definition of clinical outcome. On the contrary, the recommendations thus far are not well delineated and tend to overlap, and the past ADA position statement for pancreas transplant alone has also been applied to islet transplant alone, without differentiation. Both outcome-driven and non-outcome-driven criteria are considered in the conclusions, in an attempt to streamline indications for islet-alone or pancreas-alone transplantation.
Entities:
Keywords:
Chronic complications; Indications for transplantation; Islet transplantations; Metabolic complications; Pancreas transplantation; Type 1 diabetes
Authors: M D Bellin; R Kandaswamy; J Parkey; H-J Zhang; B Liu; S H Ihm; J D Ansite; J Witson; P Bansal-Pakala; A N Balamurugan; K K Papas; K Papas; D E R Sutherland; A Moran; B J Hering Journal: Am J Transplant Date: 2008-09-19 Impact factor: 8.086
Authors: David M Thompson; Mark Meloche; Ziliang Ao; Breay Paty; Paul Keown; R Jean Shapiro; Stephen Ho; Dan Worsley; Michelle Fung; Graydon Meneilly; Iain Begg; Mohammed Al Mehthel; Joma Kondi; Claire Harris; Blake Fensom; Sharon E Kozak; Suet On Tong; Mary Trinh; Garth L Warnock Journal: Transplantation Date: 2011-02-15 Impact factor: 4.939
Authors: Paolo Fiorina; Franco Folli; Federico Bertuzzi; Paola Maffi; Giovanna Finzi; Massimo Venturini; Carlo Socci; Alberto Davalli; Elena Orsenigo; Lucilla Monti; Luca Falqui; Silvia Uccella; Stefano La Rosa; Luciana Usellini; Giuliana Properzi; Valerio Di Carlo; Alessandro Del Maschio; Carlo Capella; Antonio Secchi Journal: Diabetes Care Date: 2003-04 Impact factor: 19.112
Authors: E B Finger; D M Radosevich; T B Dunn; S Chinnakotla; D E R Sutherland; A J Matas; T L Pruett; R Kandaswamy Journal: Am J Transplant Date: 2013-05-24 Impact factor: 8.086